R&D Institutions

Resultado da avaliação 2007 na área de Ciências da Saúde

Unidade de I&D

Centro de Investigação do Instituto Português de Oncologia do Porto (CI-IPOP) [HESC-Norte-Porto-776] visitada em 24/03/2008

Classificação: Very Good

Comentários do painel de avaliação
Sobre a unidade
This Unit was nominally composed of three groups: The Cancer Genetics Group, the Molecular Oncology Group and the Clinical Research Group. However, the Clinical Research Group comprises a service trials unit that does not depend on FCT funding and the activities of this group do not contribute to the overall research of the Unit. We have therefore not taken the activities of this group into account in the overall evaluation of the unit.
The Clinical research Group is composed of two parts neither of which depend on FCT funding. This activity is worthy of the overall mission of IPO-P but should continue to be funded by the Department of Health and commercial sponsorship. In future, if the clinical trials group is successful, it may help provide an environment of successful translational research, but it is currently too small in scale to do so. The Panel did not evaluate this group since it does not contribute to the overall scientific research of the unit.

The research output of the Cancer Genetics (776-1412) and Molecular Oncology (776-1413) groups has been rather patchy with some investigators doing high quality research, but others performing less well.

Taking into consideration the very diverse evaluation of the three groups; as indicated above, it is not reasonable to give a sort of “average” score; this would be meaningless; therefore the Panel is of the opinion that group 776-1412 (Cancer Genetics, PI: Manuel Teixeira) forms the real backbone of the Unit and that this is evaluated very good.
Sobre os grupos de investigação
Cancer Genetics Group [RG-HESC-Norte-Porto-776-1412]
The PI of group 776-1412 (Manuel Teixeira) has done very good research with a significant publication output and the PI is a leader in prostate cancer research. The scoring of the Unit as Very Good (4) overall is based on his group.
To stay internationally competitive Manuel Teixeira needs to continue to expose him to the best groups. He has a plan (for which he has obtained funding) to make regular visits to Oslo and the Panel also encourages him to foster further interactions with IPATIMUP and IBMC.
Clinical Research Group [RG-HESC-Norte-Porto-776-1414]
Molecular Oncology Group [RG-HESC-Norte-Porto-776-1413]
PI Ruiz de Medeiros has been reasonably productive and has published a few papers on candidate genes that predispose to human cancers. Although these papers have been published in moderate impact journals, in future even this output is unlikely to be maintained given the way the field is going. Without appropriately sized sample collections and expertise in genetic epidemiology (study design, study management, statistics) it is extremely unlikely this group will have any impact. The group also needs to consider how it fits within the Unit since there was no evidence of any solid collaboration with other groups.
With the exception of a single PhD student funded by FCT most of the current activity does not depend on FCT funding. The scope of the proposed future work in genetic epidemiology is not competitive. Substantial investment in case-control study design and sample collection will be needed if such work is to become competitive, but little evidence that such investment is in place was provided. FCT Unit support would be more appropriately deployed by the Director to support the research projects within the Cancer Genetics Group that are currently internationally competitive.